Join to View Full Profile
250 25th Ave NSte 100Nashville, TN 37203
Phone+1 615-320-5090
Fax+1 615-320-1225
Are you Dr. Hainsworth?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. John Hainsworth, MD is an oncologist in Nashville, Tennessee. He is currently licensed to practice medicine in Tennessee. He is a Co-Founder; Principal Investigator at Sarah Cannon Research Institute.
Education & Training
Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 1979 - 1981- Vanderbilt University Medical CenterResidency, Internal Medicine, 1976 - 1979
Vanderbilt University School of MedicineClass of 1976
Certifications & Licensure
TN State Medical License 1977 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 11 citationsMyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth...Christopher J Sweeney, John D Hainsworth, Ron Bose, Howard A Burris, Razelle Kurzrock
Journal of Clinical Oncology. 2024-01-20 - 8 citationsRandomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy.Toni K Choueiri, Camillo Porta, Cristina Suárez, John Hainsworth, Eric Voog
The Oncologist. 2022-12-09 - 48 citationsAtezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study.Claire F Friedman, John D Hainsworth, Razelle Kurzrock, David R Spigel, Howard A Burris
Cancer Discovery. 2022-03-01
Press Mentions
Precision Medicine to Expand Cancer TherapiesJuly 10th, 2016- Liquid Biopsy May Aid Treatment Decisions in Solid TumorsJuly 5th, 2016
Targeting Molecular Abnormalities with off-Label IndicationsJune 7th, 2016- Join now to see all
